Navigation Links
Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
Date:3/16/2011

SAN DIEGO and OSAKA, Japan, March 16, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that they have suspended clinical activities in an ongoing Phase 2 study examining the safety and effectiveness of the investigational combination therapy pramlintide/metreleptin for the treatment of obesity. The clinical study was voluntarily halted to investigate a new antibody-related laboratory finding with metreleptin treatment in two patients who participated in a previously completed clinical study of obesity.

"The safety of patients in our clinical programs is of paramount concern to the companies. We have taken this precaution so that we can thoroughly investigate this finding," said Orville Kolterman, M.D., senior vice president and chief medical officer of Amylin Pharmaceuticals. "Together with our partner, Takeda, we are committed to working closely with clinical investigators, regulators and outside experts to determine the best path forward."

Independent of the partnership agreement with Takeda, Amylin confirmed that today's announcement does not affect Amylin's lipodystrophy development program investigating the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy.

About Pramlintide/Metreleptin Combination Treatment

Pramlintide acetate is a synthetic analog of the natural hormone amylin, a neurohormone secreted by the pancreas that is known to play a role in the regulation of appetite, food intake and postprandial glucose concentrations. To date, approximately 8,000 individuals have received pramlintide in clinical trials, including more than 950 in obesity studies. Metreleptin (methionyl recombinant leptin; r-metHuLeptin) is an analog of human leptin, a neur
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Amylin Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
2. Amylin Pharmaceuticals to Present at the 2011 ISI Annual Conference
3. Amylin Pharmaceuticals Reports 2010 Financial Results
4. Amylin Pharmaceuticals to Webcast Year-End Financial Results
5. Amylin Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
6. Amylin Submits Clinical and Nonclinical Sections of Rolling Biologics License Application for Metreleptin to Treat Rare Forms of Lipodystrophy
7. Amylin Pharmaceuticals Reports Third Quarter Financial Results
8. Amylin Pharmaceuticals to Present at the 2010 Credit Suisse Healthcare Conference
9. Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON™
10. Amylin Pharmaceuticals to Webcast Third Quarter Results
11. Amylin Pharmaceuticals to Present at the Wedbush Life Sciences Conference 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013  Haemonetics Corporation (NYSE: HAE ) ... & EVP-Business Development, will present at The Deutsche Bank 38 ... Boston, MA on May 29, 2013 at 1:30pm ... The public may access Mr. Lindop,s presentation live ... Haemonetics Haemonetics (NYSE: HAE ) is ...
(Date:5/23/2013)... PAUL, Minn. , May 23, 2013  MGC ... Corporation), a global medical technology company, today scheduled a ... second quarter of fiscal year 2013, ended April 30, ... on Thursday, May 30, 2013. The Company will report ... 2013 after the markets close on Thursday, May 30, ...
(Date:5/23/2013)... -- Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a ... intellectual property developed and owned by Hadassah University ... research center, today announced that its portfolio company, ... the Israeli Ministry of Industry and Commerce, Office ... development and advance clinical trials. Cell Cure,s development ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
(Date:5/24/2013)... 24, 2013 The Dictation Source recently ... of clients. As a result of its National marketing ... in 20 states around the nation. , Since 1991, ... services to the healthcare industry . Dictation Source is ... their years of clinical work experience to provide the ...
(Date:5/24/2013)... New York, New York (PRWEB) May 24, 2013 ... 101 Mobility® is a leading nationwide ... accessibility solutions for both consumer and commercial applications. ... ramps, vertical platform lifts, vehicle lifts for mobility ... elevators, among others. 101 Mobility operates over 30 ...
(Date:5/24/2013)... (HealthDay News) -- About one in five parents think ... up smoking, drinking or illicit drug use, a new ... experts at the Substance Abuse and Mental Health Services ... actually one of the most influential forces helping to ... "Surveys of teens repeatedly show that parents can make ...
(Date:5/24/2013)... 2013 The SunglassFIX Photo Contest ... all while learning how to make their sunglasses, ... Contestants only need to upload pictures of themselves, ... The Sunglass Fix on Facebook in order to ... largest lens replacement online store . ...
(Date:5/24/2013)... investigational device - the Helio System (TF-FA) - being ... Valve was successfully deployed in all four patients in ... high-risk aortic insufficiency reported at EuroPCR 2013. , The ... stabilise the SAPIEN XT valve for patients with aortic ... between the transcatheter heart valve and the dock. "This ...
Breaking Medicine News(10 mins):Health News:The Dictation Source Signs Two National Hospital Chains 2Health News:The Dictation Source Signs Two National Hospital Chains 3Health News:Cortec Closes Equity Transaction with 101 Mobility 2Health News:Parents Underestimate Influence Over Teens' Substance Abuse: Survey 2Health News:Break the Sunglass Mold – Reuse 'Em, Don’t Toss 'Em then Enter the SunglassFIX Photo Contest to Win 2Health News:Feasibility trial reports deployment of new device for TAVI in aortic insufficiency 2
... children with epilepsy in developing countries are being denied ... year, according to an editorial in this weeks ... non-governmental organisations in developing countries to ensure that effective ... 35 million people with epilepsy who live in developing ...
... a screening tool to measure narrowing of the carotid artery ... tests and procedures according to researchers at the University of ... precursor to a stroke. ,Hisham Bassiouny, MD, director ... vascular surgery at the University of Chicago, presented the findings ...
... of muscle that separates the chest cavity from the ... life-threatening birth defect known as congenital diaphragmatic hernia (CDH), ... turn allows abdominal organs to migrate into the chest ... with CDH, and in fact is the major predictor ...
... landmark victory for Canadian union workers, its high court proved ... , The victory judgment against the provincial ... government to privatize support work while negating union contracts, has ... The bill was passed in 2002 to provide labor flexibility, ...
... tested on lab mice slows and may even halt the ... of rolling back this tragic disease, US researchers report on ... high blood pressure, rejuvenated ageing dopamine cells, the brain cells ... among mice was so promising that the team now plan ...
... found that the courts are seeing a number of sex ... in cases by these Juvenile offenders. ,Some ... two decades on a society saturated with sex and ... themselves victims of adult sexual predators. Others say there aren't ...
Cached Medicine News:Health News:Standards for Measuring Narrowing of Carotid Arteries too Aggressive 2Health News:Understanding and Treating Congenital Diaphragmatic Hernia 2Health News:Understanding and Treating Congenital Diaphragmatic Hernia 3Health News:Understanding and Treating Congenital Diaphragmatic Hernia 4Health News:Fangs Taken Out of Canadas Bill 29 2Health News:Test Drug Seen as Best Hope in Decades for Tackling Parkinson's 2Health News:Younger and Violent Sex Offenders on the Rise 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: